Serum levels of albumin (4-57g/L), lactate dehydrogenase (18-15,800 U/L), soluble PD-L1 (67-3,470 pg/mL), tumor type (non-small cell lung, small cell lung, biliary tract, and hepatocellular cancers), or ECOG-PS also did not affect the pharmacokinetics of durvalumab (32) (one possible reason for the inability to identify prognostic markers for durvalumab). This evidence concerns the gene CD274 and hepatocellular carcinoma.